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Critical evaluation of the claims
made
by
pharmaceutical
companies in drug promotional
material in Pakistan

be anticipated that inappropriate advertisement
claims would lead to irrational prescribing if
physicians had no any other information to follow.

Dileep Kumar Rohraa, Anwarul Hassan Gilania, Ismail
Kamal Memona, Ghazala Pervenb, Muhammad Talha
b
b
c
Khan , Hina Zafar , Rakesh Kumar

The accuracy and usefulness of drug advertisements
has been the subject of debate for more than a
century now (1). According to World Health
Organization’s (WHO) criteria for medicinal drug
promotion, “promotion refers to all the informational
and persuasive activities of manufacturers and
distributors, the effect of which is to induce the
prescription, supply, purchase and / or use of
medicinal drugs” (2). Drug promotion and marketing
make up a very large part of the activities of
pharmaceutical companies in Pakistan. For the drug
promotion, in addition to other activities, companies
usually use the written material supposedly showing
all the good and bad aspects about the concerned
drug. These advertisements can be highly informative
as long as they are critically appraised (3). However,
when these are accepted without any question, can
contribute to irrational prescribing. Ideally, drug
promotional literature should provide health care
professionals with substantial information. However,
the information contained in promotional material
may be inadequate (4) or altogether inaccurate (5).
Undoubtedly, the pharmaceutical promotional
activities have powerful influences on prescribing
behavior of the clinicians although this influence may
be more subliminal rather than overt (6, 7).
In an attempt to support and encourage the
improvement of health care through the rational use
of drugs, WHO has published ethical criteria for
medicinal drug promotion and has recommended
their implementation to its member states. As
recommended in this document, all promotionmaking claims concerning medicinal drugs should be
reliable, accurate, truthful, informative, balanced and
up to date, capable of substantiation and in good
taste. These should not contain misleading or
unverifiable statements or omissions likely to induce
medically unjustifiable drug use or to give rise to
undue risks.
Being a member state of the United Nations
Organization, efforts to regulate drug promotions in
Pakistan were also initiated with the promulgation of
the Drug Licensing, Registering and Advertising
Rules by the Ministry of Health, Government of
Pakistan. However, there is no mechanism to monitor
the drug promotional campaign by pharmaceutical
industry in Pakistan despite the fact that there is
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ABSTRACT Background. In Pakistan, there is no
mechanism to monitor the drug promotional
campaign by pharmaceutical industry despite the fact
that there is enough evidence that irrational
pharmacotherapy is increasingly encountered even in
the developed countries due to unethical practices of
pharmaceutical promotion. Objectives. To audit the
drug promotional claims made by the pharmaceutical
companies in Pakistan. Methods. Drug promotional
pamphlets and brochures containing claims for the
drugs, which were circulated by the pharmaceutical
representatives were collected from 122 general
practitioners (GPs) from Karachi and Larkana cities
of the Sindh Province. The claims were critically
analyzed and audited with the help of currently
available evidence in the medical literature. Results.
345 distinct advertisements covering 182 drugs from
different manufacturers were critically analyzed for
information content. Sixty two out of 345 (18%) of
the reviewed advertisements were adjudged to be
misleading / unjustifiable, which were again
classified as, exaggerated (32%), ambiguous (21%),
false (26%), and controversial (21%). The primary
source of information (approximately 78%) about the
newly launched drugs for the GPs was found to be
the pharmaceutical representatives followed by
hospital doctors (5%) and colleagues (5%).
Furthermore, 110 (90%) GPs were of the view that
the drug promotion has definitely an influence on
their prescribing pattern. Conclusions. Since GPs in
Pakistan rate pharmaceutical companies as their
primary source of information regarding drugs, it can
Corresponding Author: Dileep K. Rohra, Department of
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3. False: when the claim in question was totally
wrong.
4. Controversial: when the claim in question was
supported by some scientific evidence. However,
contradictory reports were also found challenging the
validity of the claim. Overall, those claims were
placed in this category, which are yet to be proven.
A structured questionnaire was also administered
from the GPs from where the promotional material
was collected. Questionnaire was developed and
piloted before the study was started and the amended
version was used in the main study. The
questionnaire was designed to gather data about the
sources of information regarding the drugs and the
knowledge, attitude and beliefs of the GPs regarding
medicinal drug promotion.

enough evidence that rational drug utilization
problems are increasingly encountered even in
developed countries due to unethical practices of
pharmaceutical promotion (8, 9).
Since promotional activities influence the
prescribing behavior of the health care providers
(10), it is of utmost importance to critically analyze
the claims made in the promotional material of the
drugs. Internationally, aspects of contents in
pharmaceutical advertising pertinent to evidencebased decision-making have been studied (11-13).
The extent to which pharmaceutical companies
promote the merits of their products and whether
such claims are supported by evidence, has not been
studied in Pakistan. The results of the present
analytical study show that unethical and biased
claims regarding the medicinal products are rampant
in Pakistan. These drug promotions influence the
prescribing behavior of the General Practitioners
(GPs) thus accounting for one of the potentially
major causes of irrational prescription.

RESULTS
A. Appraisal of drug advertisements
Three hundred and forty five distinct advertisements
covering 182 drugs from different manufacturers
were randomly collected from the GPs and critically
analyzed for information content. The total number
of claims in all 345 advertisements was 1035. This
study focused mainly on the authenticity of the
claims made by the pharmaceutical companies. Sixty
two out of 345 (18%) reviewed advertisements were
adjudged to be misleading / unjustifiable, which were
again classified as:
1. Exaggerated claims (32% of the unjustifiable
claims): As shown in Table 1, many pharmaceutical
companies in Pakistan, local as well as multinationals
were found having the tendency to exaggerate certain
facts about their products. One example of such
exaggerated claim was made for a brand of
loratadine, which states that this drug “provides
alertness without sedation all day long” or “provides
quick relief without sedation thus ensures the high
activity of performance”. These are false as well as
exaggerated claims. Admittedly, loratadine is
relatively less sedating than some of the conventional
anti-histamines but not absolutely non-sedating (14).
Furthermore; we can not think of any mechanism by
which loratidine can provide alertness or ensure the
high activity of performance. In yet one more claim
for a drug, which is a calcium supplement, it is stated
that this product “controls and prevents typical
disorders of pregnancy: low back pains, leg cramps,
lower abdominal pain”. This claim is merely made on
assumptions and there is no study and clinical
evidence available to support such a claim.

METHODS
This was a descriptive study based on critical
appraisal of drug promotional brochures, and on a
questionnaire administrated from the GPs.
Drug promotional pamphlets and brochures
containing claims for the drugs, which were
circulated by the pharmaceutical representatives were
collected from the clinics of 122 GPs. Since in
Pakistan, we do not have a data base of the practicing
GPs, randomization was not possible, therefore, the
sampling units consisted of convenient areas of one
big city (Karachi) and one relatively smaller town
(Larkana) of the Sindh Province. The claims, which
were written on those brochures were critically
analyzed
and
audited
by
one
Physician/Pharmacologist (DKR) with the help of
currently available evidence in the medical literature.
The medical literature consisted of published
research articles retrievable from the Pubmed.
Literature search was done for each claim by putting
appropriate key words. All claims were adjudged
misleading / unjustifiable, which were not supported
by available evidence. The misleading / unjustifiable
claims were further classified as follows:
1. Exaggerated: when a minor advantage of a
drug was unnecessarily magnified showing
exaggerated applications.
2. Ambiguous: when a merit of a drug in a
particular circumstance was extrapolated erroneously
to other situations.
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Table 1: List of exaggerated promotional claims by pharmaceutical companies in the light of scientific evidence.
Drug

Pharmacological
Class

Claim

Anti-claim statement

Remark

Alphacalcidol

Vitamin D3
precursor

For the treatment and
prevention of
osteoporosis

Only tried in corticosteroid-induced
osteoporosis (15)

Exaggerated /
ambiguous

Amoxicillin

Penicillin

Absence of side effects

Although relatively safer, this drug is
not devoid of side effects

Exaggerated

Bromazepam

Anxiolytic

Restores confidence

It is anxiolytic. Has nothing to do with Exaggerated
the lack of confidence associated with
personality

Buclizine

Anti-histamine

For anorexic child

Appetite stimulation and weight gain Exaggerated/
have been reported as side effects in
controversial
few studies (16), but we could not find
the anorexia in children as the
approved use of this drug.

Domperidone

Anti-emetic

Indicated in non-specific Only useful in abdominal pain
abdominal pain
associated with diabetic gastropathy
(17)

Domperidone

Anti-emetic

Provides relief in
flatulence

Effective in flatulence in a subset of
Exaggerated
patients with irritable bowel syndrome
(18)

Duxil

Neuroprotective

Improves memory

Limited data in a subset of aged
population (19)

Glibenclamide

Sulfonylurea antidiabetic

Prevents diabetic
complications

Not directly. May delay the
Exaggerated
complications through optimum blood
glucose control

Glimepiride

Sulfonylurea antidiabetic

Restores physiological
The study quoted by the advertisement Exaggerated
insulin release pattern
has shown only the effect of drug after
during meals and exercise meals not during or after exercise (20)

Hydrocortisone
sodium succinate

Corticosteroid

Life saving in
anaphylactic reaction

Steroids are never life saving in
anaphylaxis. They are used once the
condition has stabilized with other
agents (21)

Exaggerated

Lactulose

Laxative

Indicated as a first line
treatment of all types of
constipation

Lack of evidence

Exaggerated

Loratadine

H1-receptor
antagonist

Provides quick relief
Causes less but definite sedation (14)
without sedation thus
ensures the high activity
of performance

Exaggerated

Losartan

Angiotensin 1
receptor antagosist

Better tolerability than
other anti-hypertensives

In what respect? No evidence

Exaggerated/
False

L-ornithine Laspartate

Hepatoprotective

A scientifically proven
therapy for all liver
disorders and more…..

Has role in hepatic encephalopathy but Exaggerated
not all liver disorders (22)

The most effective
treatment for peripheral
neuropathy

Mildly effective in only diabetic
peripheral neuropathy (23)

Mecobalamin
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Mediforte

Multivitamin
preparation

Improves quality of life
in general weakness

Can help if weakness is due to some
vitamin deficiency

Exaggerated

Methotrexate

Anti-metabolite

Works through its antimetabolite and antineoplastic actions

How these two actions are different
from each other is not clarified.

Exaggerated

Metronidazole+
furazolidone

Anti-protozoal/anti- The magic combination All kinds of diarrhoea can not be
Exaggerated
bacterial
for all kinds of diarrhoea treated by this combination for
example travelers’ diarrhoea or
diarrhea associated with irritable bowel
syndrome

Nimodipine

Ca2+ channel
antagonist

Vitamin E

Vitamin supplement Scientific approach to
treat muscle cramps

The effective treatment
for senile dementia

Although little benefit has been
Exaggerated
observed in selected patients, its use is
not justified as anti-dementia drug (24)
Limited role in non-specific muscle
cramps (25)

Exaggerated

Table 2: List of ambiguous promotional claims by pharmaceutical companies in the light of scientific evidence.
Drug

Pharmacological
Class

Claim

Anti-claim statement

Remark

Bromazepam

Anxiolytic

Normalizes blood pressure

Limited data in a subset of Ambiguous
hypertensive population (26)

Bromazepam

Anxiolytic

Most effective in the treatment of
anxiety states without affecting
intellectual functions

Lack of evidence

Famotidine

H2 receptor antagonist The H2 receptor antagonist with
predictable response

Fosfomycin

Antibiotic

Lansoprazole

Proton pump inhibitor Supreme in its class

In what respect??

Ambiguous

Lisinopril

ACE inhibitor

Then what? Is it a benefit?

Ambiguous

Losartan

Angiotensin 1 receptor More effective control of blood
antagosist
pressure

More effective than what??

Ambiguous

Mecobalamin

Vitamin B12 analogue Effective in all kinds of nerve
disorders

Which disorders??

Ambiguous

Mecobalamin

Vitamin B12 analogue Helps repair the damaged nerves

How? No evidence

Ambiguous

Methotrexate

Anti-metabolite

Works more quickly than
commonly known drugs in
rheumatoid arthritis

Compared to what?

Ambiguous

Metoclopramide

Anti-emetic

Specific behavioural effect on
digestive system

Incomprehensible claim

Ambiguous

Mupirocin

Anti-bacterial

More effective that other topical
and systemic antibiotics in the
treatment of skin infections

Lack of evidence

Ambiguous /
exaggerated

Ranitidine

H2 receptor antagonist The most comprehensive treatment In what terms??
of duodenal and gastric ulcer

Ambiguous /
exaggerated

This is true for other H2
Ambiguous
receptor antagonists as well

First line for all kinds of infections Strange claim. No evidence Ambiguous

No prodrug
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promoted for the normalization of blood pressure. To
support the claim, a paper was quoted (26). This
study was conducted on a limited number of patients
with mild hypertension. We could not find any other
study complementing the findings of this report.
Based on a single isolated study, hypertension can
not be claimed as an approved use of bromazepam.

2. Ambiguous claims (21% of the unjustifiable
claims): During analysis, we encountered some very
vague statements about the drugs as presented in
Table 2. These statements may be only half of the
truth resulting in the misleading and misguiding of
the physicians. For instance, there was an interesting
claim about the use of bromazepam, which was being

Table 3: List of false promotional claims by pharmaceutical companies in the light of scientific evidence.
Drug
Pharmacological Class Claim
Anti-claim statement

Remark

Atenolol

β-adrenergic blocker

No risk of bronchoconstriction

Betahistine

H3-receptor antagonist

Improves neurotransmission in The study quoted by the
brain
advertisement shows the
characterization of histamine
receptors in vascular tissue (28)

Betahistine

H3-receptor antagonist

Does not sedate

False
The study quoted by the
advertisement does not support the
claim (29)

Calcium
supplement

Nutritional supplement

Controls and prevents typical
disorders of pregnancy: low
back pains, leg cramps, lower
abdominal pain

Lack of evidence

Famotidine

H2 receptor antagonist

The most economical anti-ulcer Cimetidine and ranititidine are
in Pakistan
more economical in Pakistan

False

Fosfomycin

Antibiotic

No drug interaction

Significant drug interactions (30)

False

Lisinopril

ACE inhibitor

The real ACE inhibitor

Are captopril or enalapril etc. fake False
inhibitors of ACE?

Liv. 52 DS

A food supplement

FDA approved for
hepatoprotection

We could not find any approval on False
the website of FDA

Loratadine

H1-receptor antagonist

Provides alertness

Lack of evidence

False

Recommended in low back pain Lack of evidence

False

Rarely associated with side
effects like bone marrow
suppression and acute
disturbances of liver functions

False

Mecobalamin
Methotrexate

Anti-metabolite

Micronized
purified
flavonoidic
fraction

Risk of bronchoconstriction is
there (27)

Frequently associated with bone
marrow suppression and
hepatotoxicity (31-34)

False
False

False

A decisive therapeutic benefit in Lack of evidence
acute hemorrhoidal attacks

False

False /
exaggerated

Naproxen

NSAID

Is about 20 times more effective Lack of evidence
than aspirin, ibuprofen

Nimesulide

COX 2 inhibitor

No drug interactions

Although few but significant drug False
interactions have been described
(35)

Reduces bronchial congestion
and spasm of whooping cough

Lack of evidence

The only selective blocker of
α1-receptors

Prazosin and doxazosin are other False
selective blockers

Promethazine + Anti-histamine/opioid
pholcodine
cough
suppressant
Terazosin

α-adrenergic blocker
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suppression and acute disturbances of liver functions.
Contrary to this claim, there are various reports,
which have shown that long term treatment with this
drug is frequently associated with bone marrow
suppression and hepatotoxicity (31-34).

3. False Claims (26% of the unjustifiable claims): As
depicted in Table 3, certain companies were found to
promote their products on statements that were
entirely false. For example, we observed a claim on a
promotional material that methotrexate is rarely
associated with side effects like bone marrow

Table 4: List of Controversial promotional claims by pharmaceutical companies in the light of scientific evidence.
Drug

Pharmacological
Class

Claim

Anti-claim statement

Remark

Cefradine

Cephalosporin

Resistance to β-lacatamases
is unmatched by any other
cephalosporin

Many other cephalosporins
are more resistant (36)

Controversial

Cetirizine

H1-receptor antagonist Remarkable mast cell
stabilizing effect

No such effect has been
Controversial/False
observed in many studies (37)

Citalopram

Anti-depressant

No drug interactions

Although few but significant Controversial
drug interactions have been
described (38)

Citicoline

Neuroprotective

improves neurocognition

Efficacy of long term
treatment still under
investigation (39, 40)

Controversial

Effective in impotence

Lack of evidence

Controversial/False

Dihydroergocryptine Dopamine agonist
Famotidine

H2 receptor antagonist Prevents recurrence of peptic Lack of evidence
ulcer

Glibenclamide +
metphormin

Sulfonylurea +
biguanide antidiabetic

Controversial

A winning combination

Higher incidence of mortality Controversial
when treated with the
combination (41, 42)

Glucosamine sulphate Natural product

Stimulates biosynthesis of
chondroitin sulphate

Exogenous glucosamine does Controversial
not stimulate biosynthesis of
chondroitin sulphate (43)

Losartan

Angiotensin 1
receptor antagosist

Better anti-hypertensive
response as compared to
valsartan

Valsartan has been shown to Controversial
be more efficacious (44)

Mebeverine

Anti-spasmodic

A safe treatment for Irritable Hospitalization increased
Bowel Syndrome
after use of mebeverine (45)

Controversial

Methotrexate

Anti-metabolite

Drug of choice for the
treatment of rheumatoid
arthritis

Lack of evidence

Controversial

Nimesulide

COX 2 inhibitor

Well tolerated by kidneys

Death due to nimesulideControversial
induced renal failure has been
reported (46)

Silver sulphadiazine

Antibiotic

Accelerates wound healing

Impairment of wound healing Controversial
has been shown in many
studies (47)
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prescribed their medications based on the information
provided by them.

4. Controversial claims (21% of the unjustifiable
claims): As shown in Table 4, we found that some of
the promotional material contained claims that have
not been proven yet. These claims are still under
investigation. For example, some manufacturers of
oral
hypoglycemic
drugs
are
promoting
glibenclamide and metformin as a “Winning
combination”. But the other side of the story is that
not enough studies have been conducted to prove the
efficacy of the combination. As a matter of fact few
of the studies that we came across showed higher
incidence of mortality in patients treated with the
combination compared to sulfonylurea alone (41, 42).
B. Source of information for medical practitioners
about the drugs
A total of 150 GPs were contacted personally for
filling a questionnaire. Out of which 122 GPs
responded positively (response rate; 81.3%), while
the rest refused to participate in the study due to one
or other reasons. All the GPs selected were solo
private practitioners not affiliated with any hospital
or group. The characteristics of the GPs, who
participated in this study, are shown in Table 5.

Table 6: Percentage of family physicians’ rating for the
source of information about the new drugs prescribed by
him / her
Source of information about the drugs
% (n = 122)

82.0% (100)

Females

18.0% (22)

Age

39.2 ± 4.5 years

Years since last degree

10.1 ± 2.4 years

Mean years of practice

13.3 ± 3.6 years

No of patients seen per week

132 ± 7.7

0.8

Medical books

1.6

Newspapers

0

Drug bulletins

0

Pakistan National Formulary

0

PharmaGuide / Quick index of medical
products

1.6

Colleagues

4.9

Consultants

4.9

Pharmaceutical Representatives

77.9

Sponsored meetings

3.3

Direct mail

0

Journal advertisements

0.8

Hospital doctors – Discharge letters, patients 4.1
etc.

Table 5: Characteristics of General Practitioners who
participated in the study (n = 122)
Characteristics
Males

Medical journal articles

Internet

0

DISCUSSION
This is the first analytic survey of pharmaceutical
advertising claims in Pakistan. Previous studies have
shown that medical practitioners are reliant on the
pharmaceutical industry for much of their drug
information in Pakistan (48) or elsewhere (49). We
also observed that despite the apprehensions about
the truthfulness of the advertised claims, the GPs rate
the pharmaceutical advertisement as the most
important source of information about the drugs.
Furthermore, a majority of physicians are of the view
that drug marketing has undoubtedly an influence on
their prescribing practices. The drug promotional
practices carried out by the pharmaceutical industry
would have undergone a sea-change from the early
days. Initially it began as a genuinely informative
exercise to keep the doctors informed about the
company’s products. Today it has become more like
a commercial relationship. Although assessment of
the truthfulness of the drug promotional claims is
very complex, we tried to analyze this keeping in
mind the objectives of the evidence-based medicine.
Each claim was appraised objectively with the help
of available evidence in the medical literature.
The international pharmaceutical industry is

The area of study included the cities of Karachi and
Larkana of the Sindh Province. Since the response of
GPs from the two cities was not different, the
answers from all the doctors belonging to both cities
were pooled together. The doctors were asked to
identify the primary source of information of the
drugs for them. As shown in Table 6, the primary
source of information (approximately 78%) about the
newly launched drugs for the GPs was found to be
the pharmaceutical representatives followed by
hospital doctors (5%) and colleagues (5%) as stated
by them. Furthermore, 110 (90%) GPs were of the
view that the drug promotion has definitely an
influence on their prescribing pattern. Interestingly,
although 54% of the GPs did not believe completely
in the advertised claims by the pharmaceutical
companies, they continued to follow their version and

56

J Pharm Pharmaceut Sci (www.cspsCanada.org) 9(1):50-59, 2006

Concluding, the results of the present study show
that unethical practices regarding the medicinal drug
promotion are rampant in Pakistan and it is suggested
that physicians should be cautious and critical in
assessment of advertised claims of greater efficacy,
safety or convenience made by the pharmaceutical
companies. Furthermore, it is high time that efforts
directed towards an institutionalized implementation
of ethical criteria for the promotion of drugs be made.

rightly proud of advances made in quality control of
pharmaceutical production and chemical purity.
Unfortunately, as many examples in the present
survey indicate flaws in drug promotional claims, it
has much less to be proud of in the quality of the
promotional information. Many of the claims made
by them were not supported with data. When the text
of the advertisements was critically evaluated, we
found a significant ratio (18%) of claims to be
unjustified or misleading. This carries a marked
impact on the overall health delivery system. Since
GPs in Pakistan rate pharmaceutical companies as
their primary source of information regarding drugs,
it can be anticipated that inappropriate advertisement
claims would lead to improper prescribing if
physicians had no other information on which to
depend. The outcome of the irrational prescription
may be that the drugs can be used when these are not
needed or new, more expensive products are
prescribed, when these bring no clear advantage over
cheaper
alternatives.
The
potential
health
consequences for the consumers are not benign; for
instance, treatment failures from the use of the wrong
drugs, patients suffering unnecessary adverse effects,
increase in antibiotic-resistant microorganisms; and
the waste of patients’ money and national health
resources.
In such a scenario immediate remedial measures
need to be taken. Starting from the root cause of this
malpractice, we need to have well-defined and
updated ethical criteria for the marketing of
medicinal drugs by the pharmaceutical companies.
These criteria need to be enforced by a public
institution, preferably the Ministry of Health. In order
to ensure that the ethical criteria are being
implemented, there is a need for screening of printed
promotional material and active monitoring of other
forms of promotion. In cases of non-compliance or
malpractices, effective sanctions and mechanisms to
correct misinformation should be well-defined.
Secondly, we need to teach our doctors the art of
critical appraisal of medicinal drug promotion
possibly during their undergraduate training so that
they would be able to write rational prescriptions.
Another step towards improvement could be
reassessing the knowledge of all practicing doctors
regarding drugs available in the market. This
assessment should be according to the international
standards and should be compulsory for the doctor to
have an attempt after a specified time. This would
compel the doctors to look up to the authentic
medical literature for reference instead of relying
solely on the promotional material.
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